Investment Rating - The investment rating for the company is "Buy" (maintained) with a target price of 56.94 CNY [1][7]. Core Views - The company has shown a recovery in performance with simultaneous expansion in domestic and international markets. The revenue for the first half of 2025 reached 270 million CNY, representing a year-on-year increase of 20.5%, while the net profit attributable to the parent company was 70 million CNY, up 5.5% year-on-year [11]. - The company is focusing on enhancing its domestic presence and building its own brand, with domestic revenue for the first half of 2025 at 70 million CNY, a slight increase of 1.7% year-on-year. The sales of medical optical products in the domestic market grew by 48% year-on-year [11]. - The company has made significant advancements in research and development, with R&D investment of 33.215 million CNY in the first half of 2025, an increase of 7.8% year-on-year. This includes the trial production of new medical instruments and the application of AI technology to improve endoscopic image quality [11]. Financial Summary - The company’s revenue projections for 2025-2027 have been adjusted to 556 million CNY, 674 million CNY, and 835 million CNY respectively, with year-on-year growth rates of 25.6%, 21.1%, and 23.9% [9][7]. - The earnings per share (EPS) forecast for 2025-2027 has been revised to 1.46 CNY, 1.69 CNY, and 2.04 CNY respectively, reflecting a downward adjustment from previous estimates [7]. - The company’s gross margin is expected to remain stable, with projections of 64.7%, 64.9%, and 63.8% for the years 2025, 2026, and 2027 respectively [9].

Investment Rating - The investment rating for the company is "Buy" (maintained) with a target price of 56.94 CNY [1][7] Core Views - The company has shown a recovery in performance with simultaneous expansion in domestic and international markets. The short-term performance is under pressure, but the order volume is expected to recover [5][11] - The company achieved a revenue of 270 million CNY in H1 2025, representing a year-on-year increase of 20.5%, with a net profit attributable to the parent company of 70 million CNY, up 5.5% year-on-year [11] - The company is actively expanding its overseas business and has established production lines in Thailand to mitigate tariff pressures from the US market [11] - Domestic sales have shown stability, with a 1.7% year-on-year increase in revenue, while medical optical products saw a significant growth of 48% [11] Financial Summary - Revenue projections for 2025-2027 have been adjusted to 556 million CNY, 674 million CNY, and 835 million CNY respectively, with corresponding year-on-year growth rates of 25.6%, 21.1%, and 23.9% [9][7] - The earnings per share (EPS) forecast for 2025-2027 is adjusted to 1.46 CNY, 1.69 CNY, and 2.04 CNY respectively [7] - The company’s gross margin is expected to remain stable around 64.7% in 2025, with a net margin of 31.6% [9][7]

Investment Rating - The report maintains a "Buy" rating for the company, with a target price of 16.20 CNY based on a 20x PE for 2026 [5][3]. Core Views - The company's core game "Yihuan" is expected to launch in 2026, contributing significantly to revenue growth. The forecasted net profit for the company is 0.827 billion, 1.564 billion, and 1.806 billion CNY for 2025, 2026, and 2027 respectively, reflecting a recovery in profitability [3][10]. - The company has seen a strong performance in its existing games, particularly "Zhu Xian World," which has driven revenue growth in the first half of 2025 [10]. Financial Summary - The company's revenue for 2023 is projected at 7.791 billion CNY, with a year-on-year growth of 1.6%. However, a decline of 28.5% is expected in 2024, followed by a recovery with growth rates of 29.1% and 48.6% in 2025 and 2026 respectively [4][12]. - The gross profit margin is expected to stabilize around 58.2% in 2025 and increase to 63.9% in 2026, indicating improved profitability as new games are launched [4][12]. - The net profit margin is projected to recover from -23.1% in 2024 to 14.6% in 2026, reflecting a significant turnaround in the company's financial health [4][12].

宏观经济 | 动态跟踪 降息前后美国经济仍疲弱 ——海外札记 20250903 研究结论 风险提示 经济基本面不确定性。 关税政策不确定性。 降息落地进度不及预期的风险。 地缘政治形势走向的不确定性。 报告发布日期 2025 年 09 月 04 日 | 王仲尧 | 021-63325888*3267 | | --- | --- | | | wangzhongyao1@orientsec.com.cn | | | 执业证书编号：S0860518050001 | | | 香港证监会牌照：BQJ932 | | 吴泽青 | wuzeqing@orientsec.com.cn | | | 执业证书编号：S0860524100001 | | 孙金霞 | 021-63325888*7590 | | | sunjinxia@orientsec.com.cn | | | 执业证书编号：S0860515070001 | | 降息按下快进键：——海外札记 20250825 | 2025-08-27 | | --- | --- | | 美国通胀风险未能阻碍市场上行：——海 | 2025-08-19 | | 外札记 20250818 ...

新兴市场及车载业务推动业绩增长 核心观点 公司主要财务信息 | | 2023A | 2024A | 2025E | 2026E | 2027E | | --- | --- | --- | --- | --- | --- | | 营业收入(百万元) | 21,021 | 25,731 | 31,446 | 37,386 | 44,199 | | 同比增长 (%) | 5% | 22% | 22% | 19% | 18% | | 营业利润(百万元) | 667 | 3,271 | 5,037 | 6,495 | 8,044 | | 同比增长 (%) | -49% | 391% | 54% | 29% | 24% | | 归属母公司净利润(百万元) | 556 | 3,323 | 4,323 | 5,416 | 6,469 | | 同比增长 (%) | -44% | 498% | 30% | 25% | 19% | | 每股收益（元） | 0.46 | 2.76 | 3.58 | 4.49 | 5.36 | | 毛利率(%) | 21.8% | 29.4% | 31.1% | 31.3% | 31.7% | | 净 ...

Investment Rating - The report maintains a "Buy" rating for Geely Automobile [4][7]. Core Views - Geely's sales continue to improve, with a projected increase in market share [2]. - The company has adjusted its earnings per share (EPS) forecasts for 2025-2027 to 1.49, 1.75, and 2.12 RMB respectively, while maintaining a target price of 22.35 RMB, equivalent to 24.54 HKD [4]. Financial Performance Summary - **Revenue Forecast**: - 2023A: 179,204 million RMB - 2024A: 240,194 million RMB - 2025E: 319,444 million RMB (33.0% YoY growth) - 2026E: 381,363 million RMB (19.4% YoY growth) - 2027E: 442,685 million RMB (16.1% YoY growth) [6]. - **Operating Profit**: - 2023A: 3,806 million RMB - 2024A: 7,644 million RMB (100.8% YoY growth) - 2025E: 14,116 million RMB (84.7% YoY growth) - 2026E: 16,739 million RMB (18.6% YoY growth) - 2027E: 20,314 million RMB (21.4% YoY growth) [6]. - **Net Profit**: - 2023A: 5,308 million RMB - 2024A: 16,632 million RMB (213.3% YoY growth) - 2025E: 15,121 million RMB (-9.1% YoY decline) - 2026E: 17,735 million RMB (17.3% YoY growth) - 2027E: 21,451 million RMB (21.0% YoY growth) [6]. - **Earnings Per Share (EPS)**: - 2023A: 0.53 RMB - 2024A: 1.65 RMB - 2025E: 1.49 RMB - 2026E: 1.75 RMB - 2027E: 2.12 RMB [6]. - **Profitability Ratios**: - Gross Margin: Expected to increase from 15.3% in 2023A to 16.7% in 2027E - Net Margin: Expected to improve from 3.0% in 2023A to 4.8% in 2027E - Return on Equity (ROE): Expected to rise from 6.6% in 2023A to 14.6% in 2027E [6]. Sales Performance Summary - In August, Geely's total sales reached 250,200 units, a year-on-year increase of 38.0% and a month-on-month increase of 5.2% [11]. - New energy vehicle sales in August were 147,300 units, showing a year-on-year growth of 95.2% [11]. - The company has achieved 63.2% of its annual sales target of 3 million units by the end of August [11]. Product Development and Market Position - The Galaxy brand's sales are on the rise, with significant contributions from new product launches [11]. - The Galaxy A7 and Galaxy M9 are expected to enhance market competitiveness, with pre-sales showing strong demand [11]. - Zeekr 9X has also shown promising pre-sale figures, indicating strong consumer interest in high-end models [11].

Investment Rating - The report maintains a "Buy" rating for the company with a target price of 47.30 CNY, reflecting a reasonable market value of 273.54 billion CNY [4][7]. Core Insights - The company has shown a narrowing loss with a significant increase in commercial product sales, leading to a 29% year-on-year revenue growth in the first half of 2025, achieving 0.19 billion CNY. The net profit attributable to the parent company was -1.19 billion CNY, a 44% reduction in loss compared to the previous year [12]. - The company is actively expanding the indications for its approved products, with ongoing clinical trials for both Beifutini and Gexorase, which are expected to enhance their market presence [12]. - The research pipeline is well-structured, with several promising candidates in advanced clinical stages, indicating strong potential for business development opportunities [12]. Financial Forecast and Analysis - The company’s revenue is projected to decline from 186 million CNY in 2023 to 141 million CNY in 2025, before rebounding to 323 million CNY in 2026 and 525 million CNY in 2027, reflecting a growth rate of 129.3% and 62.6% respectively [6][15]. - The net profit attributable to the parent company is expected to improve from -284 million CNY in 2023 to -203 million CNY in 2025, with a further reduction to -94 million CNY by 2027 [6][15]. - The gross margin is forecasted to remain high, around 97.2% in 2025, while the net margin is expected to improve significantly from -144.0% in 2025 to -17.8% in 2027 [6][15].

Investment Rating - The report maintains a "Buy" rating for the company [3][6]. Core Views - The company's profitability is improving, with significant growth expected from the product Didasyn [10]. - The revenue forecast for 2025 has been adjusted to 4.33 billion yuan, with EPS estimates revised to 0.95 yuan for 2025, 1.10 yuan for 2026, and 1.25 yuan for 2027 [3][5]. - The target price is set at 25.30 yuan based on a 23x PE ratio for 2026 [3]. Financial Performance Summary - Revenue for 2023 is projected at 3.999 billion yuan, with a growth rate of 5.8%. For 2024, revenue is expected to reach 4.159 billion yuan, growing at 4.0% [5][12]. - Operating profit is forecasted to be 714 million yuan in 2023, with a decline of 5.6%, but is expected to rise to 844 million yuan in 2024, reflecting an 18.1% increase [5][12]. - Net profit attributable to the parent company is estimated at 619 million yuan for 2023, with a decrease of 6.5%, and is projected to grow to 712 million yuan in 2024, a 15.0% increase [5][12]. - The gross margin is expected to improve from 50.6% in 2023 to 51.5% in 2025, while the net margin is projected to increase from 15.5% to 18.9% over the same period [5][12]. - The company’s return on equity (ROE) is expected to rise from 11.6% in 2023 to 12.8% in 2025 [5][12].

Investment Rating - The report maintains a "Buy" rating for the company [5] Core Views - The company's performance is under short-term pressure, but improvement is expected in the second half of the year [1] - Revenue and profit forecasts have been adjusted, with earnings per share projected at 0.61, 0.70, and 0.86 yuan for 2025-2027, respectively [2] - The target price is set at 12.81 yuan based on a 17x P/E ratio for 2026 [2] Financial Performance Summary - The company reported a revenue of 4,123 million yuan in 2023, with a projected decline to 3,837 million yuan in 2025, followed by a recovery to 4,429 million yuan in 2026 and 5,181 million yuan in 2027 [4] - The gross margin is expected to improve from 52.9% in 2023 to 65.0% by 2027 [4] - The net profit attributable to the parent company is forecasted to increase from 563 million yuan in 2023 to 852 million yuan in 2027, with a significant jump of 51.9% in 2025 [4] - The company’s earnings per share are projected to rise from 0.57 yuan in 2023 to 0.86 yuan in 2027 [4] Market and Product Insights - The company is experiencing challenges in raw material and formulation sales, but there is potential for recovery as export prices stabilize and the impact of centralized procurement diminishes [8] - The overseas market is becoming a new growth driver, with a reported revenue of 5.41 billion yuan from international operations, reflecting a 5.1% year-on-year increase [8] - The company has a robust pipeline of new products, with several new drugs and complex formulations expected to receive approval soon, enhancing future growth prospects [8]

Investment Rating - The investment rating for the company is "Buy" (maintained) with a target price of 232.08 CNY [1][10] Core Views - The company shows resilient performance with steady growth in revenue, despite a slight decline in profit margins due to product mix adjustments [4][9] - The company is focusing on expanding its market presence outside of Shanxi, with significant growth in regions like the Yangtze River Delta and Pearl River Delta [9] - The product portfolio, particularly the "Glass Fen" and "Qinghua 20" series, is expected to maintain strong demand and adaptability in various market conditions [9] Financial Performance Summary - Revenue for 2023 was 31,928 million CNY, with a year-on-year growth of 21.8%. The forecast for 2025 is 35,471 million CNY, reflecting a slight decline of 1.5% [7] - Operating profit for 2023 was 14,224 million CNY, with a year-on-year growth of 30.8%. The forecast for 2025 is 15,952 million CNY, indicating a decrease of 3.5% [7] - Net profit attributable to the parent company for 2023 was 10,438 million CNY, with a year-on-year growth of 28.9%. The forecast for 2025 is 11,803 million CNY, showing a decline of 3.6% [7] - Earnings per share (EPS) for 2023 was 8.56 CNY, projected to be 9.67 CNY in 2025 [7][10] Market Performance Summary - The company's stock price as of September 2, 2025, was 200.14 CNY, with a 52-week high of 232.57 CNY and a low of 142 CNY [1] - The company's absolute performance over the past week was -3.73%, with a 12-month performance of 23.75% [2]